More Articles

Avanir and Wockhardt settle Nuedexta patent dispute Generics/News | Posted 20/09/2013

US-based Avanir Pharmaceuticals (Avanir) announced on 6 September 2013 that it had entered into a settlement agreement with Wockhardt USA, the US subsidiary of India-based generics maker Wockhardt,...

Failed biosimilars company to be sold Biosimilars/News | Posted 20/09/2013

The assets of biosimilars developer Elona Biotechnologies (Elona) will be auctioned on 27 September 2013 unless sold before 6 September 2013.

EC approves first monoclonal antibody biosimilar Biosimilars/News | Posted 13/09/2013

Hospira announced on 10 September 2013 that it had received European Commission (EC) approval for its biosimilar monoclonal antibody infliximab (Inflectra), a first in Europe.

South Africa introduces new patent policy Policies & Legislation | Posted 13/09/2013

South Africa has become the latest country to examine its patent laws with a view to curbing patent evergreening and increasing production of generics.

California Assembly passes biosimilars substitution bill Policies & Legislation | Posted 13/09/2013

California has taken a step closer to adopting legislation which would authorize pharmacists to substitute an FDA-approved biosimilars for their reference biologicals with a notification to prescri...

Actavis confirms Rayos patent challenge and Warner Chilcott acquisition Generics/News | Posted 13/09/2013

Actavis has filed for US approval for a generic version of the anti-inflammatory or immunosuppressive agent Rayos (prednisone). The company also confirmed its proposed acquisition of Warner Chilcott.

Celltrion applies for biosimilar infliximab approval in Japan Biosimilars/News | Posted 13/09/2013

On 11 September 2013, South Korean biotechnology company Celltrion announced that it had filed for approval of Remsima, its biosimilar infliximab monoclonal antibody, with Japan’s Ministry of Healt...

Ranbaxy to expand Russian portfolio Generics/News | Posted 13/09/2013

Generics manufacturer Ranbaxy Laboratories (Ranbaxy) has been in the Russian pharmaceuticals market for 20 years and is now considering expanding its product offering in the country.